In its brand new 200,000 sq ft GMP facility, set to operate this spring, Enzymotec shall consolidate its production and would significantly increase its capacity in an effort to meet ever-growing customers demand for its Krill Oil worldwide. "Additional ingredients shall be added to its product line, mainly for the pharma industry," the company says.
"As time passes we are happy to see that a growing number of Krill Oil customers realize that our product contains higher concentration of phospholipids and Astaxanthin which make it better" says Elzaphan Hotam, CEO of the US operations. "Clearly, what customers value the most seems to be the quality of the product and the service which we provide. We firmly believe that transparency of our production methods, assay methodology and technical know-how will definitely serve this growing segment of the industry for years to come," added Hotam.
Recently, the company expanded its product line into a greater variety of Krill-based combinations, including Krill-based grades, PS/Krill combos and a new line of products based on fish sources, set to expand the uses of marine phospholipids.
Enzymotec is a developer and manufacturer of innovative, lipid-based biofunctional solutions for orthomolecular medicine, dietary supplements and advanced infant nutrition. Key products are: Sharp PS® line of products- phosphatidylserine based ingredients for cognitive improvement, InFat® - structured fat for infant formulas, CardiaBeat® offering a broad health effect to reduce CVD risks and Krill Oil+™.